Tagrix is the 1st global generic of osimertinib. This drug is a third generation EGFR inhibitor. Osimertinib (Tagrix) is the 1st and only drug of its kind approved by USFDA for the treatment of epidermal growth factor receptor (EGFR) positive Non- Small Cell Lung Cancer (NSCLC) patient with T790M mutation.
Tagrix- 80mg (Osimertinib) Price & Offers
- Post author:admin
- Post published:April 7, 2016
- Post category:Anti Cancer / Anti Viral
- Post comments:0 Comments